Market Vectors® Pharmaceutical ETF

Most Recent

  • uploads///Chart
    Earnings Report

    Major Developments for Johnson & Johnson in 3Q16

    Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Teva Pharmaceutical in 2017

    Following the completion of its acquisition of Allergan’s Actavis Generics business on August 2, 2016, Teva Pharmaceutical plans to focus on realizing the deal’s synergies in 2017.

    By Margaret Patrick
  • uploads///Costs
    Earnings Report

    Bristol-Myers Squibb’s Profitability and Financial Guidance

    Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Gardasil and What It Could Mean

    Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.

    By Mike Benson
  • uploads///PFE MDVN deal
    Company & Industry Overviews

    What’s the Story behind the Pfizer-Medivation Deal?

    Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.

    By Jillian Dabney
  • uploads///Growth
    Earnings Report

    Johnson & Johnson’s 3Q15 Changes in Growth Rate

    Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    This Space Presents a Market Opportunity for Valeant

    In Valeant’s 2Q16 earnings, Xifaxan reported a year-over-year (or YoY) increase in monthly prescriptions of about 28.0%.

    By Margaret Patrick
  • uploads///freestocks org  unsplash
    Company & Industry Overviews

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

    By Mike Benson
  • uploads///generic drug savings
    Company & Industry Overviews

    Will Generic Drugs Help Curb Healthcare Costs?

    Reducing medical costs would be a high priority in all economies, and generic drugs could provide a solution.

    By VanEck
  • uploads///revenue ee
    Earnings Report

    How Did Valeant Fare in 2Q16?

    Valeant Pharmaceuticals (VRX) announced earnings for 2Q16 on August 9, 2016.

    By Jillian Dabney
  • uploads///Chart  GSK
    Company & Industry Overviews

    How GlaxoSmithKline Stock Performed in 1Q18

    GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Kisqali BTD
    Company & Industry Overviews

    Novartis Receives 2 Breakthrough Therapy Designations in January

    In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

    Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

    By Mike Benson
  • uploads///Chart  Other
    Earnings Report

    A Look at Bristol-Myers Squibb’s Other Segments in 1Q17

    Bristol-Myers Squibb’s (BMY) other segments include the Neuroscience segment, the Cardiovascular segment, and the Immuno-Science segment.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Continues to Be a Leader in the Global Insulin Market

    Accounting for a ~46% market share, Novo Nordisk (NVO) is expected to continue to benefit from the positive trends in the global insulin market

    By Margaret Patrick
  • uploads///joshua coleman  unsplash
    Earnings Report

    Sanofi Misses Wall Street Estimates for 1Q18 Revenues

    Sanofi (SNY) missed Wall Street analysts’ estimates for revenues today but beat estimates for earnings per share.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Strengthens Its Position in the Virology Segment

    In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

    By Margaret Patrick
  • uploads///Oncology
    Earnings Report

    AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?

    AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.

    By Mike Benson
  • uploads///patent cliff
    Company & Industry Overviews

    Drug Patent Expirations: $190 Billion Is Up for Grabs

    According to estimates by Evaluate Pharma, a whopping $120 billion in sales was lost to patent expirations between 2009 and 2014.

    By VanEck
  • uploads///ANR
    Company & Industry Overviews

    What Do Analysts Recommend for Valeant after Recent Happenings

    The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.

    By Jillian Dabney
  • uploads///growth of generics
    Company & Industry Overviews

    Rx for Growth? Why Generic Drugs Are Gaining Traction

    Rx for Growth? The trillion-dollar pharmaceutical industry has historically been dominated by a few major companies that create and supply the most important branded prescriptions on the market. Recent trends, however, point to the growth of the newest pharma blockbusters: generics. Today, approximately 60% of Americans take prescription drugs;[1. “Trends in Prescription Drug Use Among […]

    By VanEck
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca May Witness a Fall in 2017 Net Profit Margin

    Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Oncology Segment: Another Growth Platform for AstraZeneca?

    The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.

    By Mike Benson
  • uploads///Recent wins
    Earnings Report

    Brodalumab, Oral Relistor among Valeant’s Recent Wins

    Valeant’s (VRX) recent wins include the FDA’s advisory committee vote in favor of approving brodalumab for the indication of mild to moderate psoriasis.

    By Jillian Dabney
  • uploads///Animal Health Segment
    Earnings Report

    How Did Merial Contribute to Sanofi’s 2Q15 Growth?

    Merial reported total revenues of 691 million euros, a 14.2% increase at constant exchange rates over 2Q14.

    By Mike Benson
  • uploads///sales growth india generic drugs
    Company & Industry Overviews

    Why India Is So Important for Global Pharma

    There are several compelling reasons for India’s rising pharma stature, including inexpensive labor, strong government support, and lower production costs.

    By VanEck
  • uploads///demographics
    Macroeconomic Analysis

    How Demographics Are Shaping Generic Drug Growth

    The generic drugs industry is likely to sustain robust growth in the coming years, and demographics are a key piece of the puzzle! In fact, demographics are shaping generic drug growth in a huge way.

    By VanEck
  • uploads///Tailwinds
    Company & Industry Overviews

    Indian Pharma: Analyzing the Tailwinds for Growth

    India’s strength within the pharmaceutical sector can be seen in the sheer number of pharmaceutical manufacturing plants in the country, which number approximately 10,500.

    By VanEck
  • uploads///Chart
    Company & Industry Overviews

    Inside Novartis’s Eye Care Performance in 4Q16

    Alcon, NVS’s eye care segment, saw its 4Q16 revenues fall ~2% to ~$1.4 billion, including no change in sales but a -2% impact from foreign exchange.

    By Mike Benson
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    What Analysts Expect from Pfizer in the Years to Come

    Due to Pfizer’s (PFE) strong Innovative Products business and product pipeline, analysts estimate that it will generate $0.54 in earnings per share in 1Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Behind Bristol-Myers Squibb’s Continued Growth in 1Q16

    Bristol-Myers Squibb (BMY) reported a growth of 9% in 1Q16. Analyst estimates forecast a high-single-digit growth to low-double-digit in revenues in 2016.

    By Mike Benson
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • uploads///Xyrem
    Company & Industry Overviews

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    A Look at Novartis’s Valuation on October 9

    Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue.

    By Mike Benson
  • uploads///simone van der koelen  unsplash
    Earnings Report

    Merck Witnessed 5% Growth in Q2 2018

    Merck (MRK) generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How Pfizer’s Business Segments Have Performed

    As discussed, Pfizer’s (PFE) business is divided into two business segments, Innovative Health and Essential Health.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for Pfizer in March 2018

    Pfizer (PFE) surpassed Wall Street analysts’ consensus estimate for EPS (earnings per share) in 4Q17, reporting EPS of $0.62 compared to the estimate of $0.56.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Sandoz Performed in 4Q17

    Sandoz reported flat revenues at ~$2.6 billion during 4Q17 as compared to 4Q16.

    By Mike Benson
  • uploads///headache _
    Company & Industry Overviews

    What’s Novartis’s Valuation in March 2018?

    Novartis reported earnings per share of $1.21 on revenues of ~$12.9 billion in 4Q17.

    By Mike Benson
  • uploads///pill _
    Company & Industry Overviews

    What’s AstraZeneca’s Valuation in March 2018?

    AstraZeneca surpassed Wall Street analysts’ estimates with EPS of $1.03 on revenues of ~$5.8 billion in 4Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi’s Valuations in February 2018

    Sanofi (SNY) reported revenues of ~8.7 billion euros in 4Q17, a decline of ~2.0% in revenues compared to ~8.9 billion euros in 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi Pasteur’s 4Q17 Performance

    Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17, reflecting 8.7% growth in operating revenues compared to 4Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline’s Valuations after Its 4Q17 Earnings

    On February 15, 2018, GlaxoSmithKline traded at a forward PE multiple of 12.9x, which is lower than the industry average of 13.3x.

    By Mike Benson
  • uploads///VRX divestments
    Company & Industry Overviews

    Inside Valeant Pharmaceuticals’ Recent Divestments

    Valeant Pharmaceuticals (VRX) was granted the worldwide exclusive licensing rights for manufacturing and selling the EyeGate 2 delivery system.

    By Kenneth Smith
  • uploads///ABLYNX_TRANSACTION_HIGHLIGHTS
    Company & Industry Overviews

    Highlights of Sanofi’s 3.9 Billion Euro Ablynx Acquisition

    On January 29, 2018, Sanofi announced its acquisition of Belgium-based Ablynx for 45 euros per share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q17 Earnings: Innovative Medicines Business

    Novartis’s (NVS) Innovative Medicines business reported 4.0% growth in operating revenues, while there was a 2.0% positive impact of foreign exchange in 4Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyst Ratings and Recommendations for Merck & Co.

    Wall Street analysts estimate Merck & Co.’s (MRK) top line to increase 3.7% to $10.5 billion for 4Q17 compared to $10.1 billion in 4Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Dolutegravir Franchise to Drive GlaxoSmithKline’s HIV Portfolio

    In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 1.1 billion pounds from the sale of its HIV products.

    By Margaret Patrick
  • uploads///Tasigna
    Company & Industry Overviews

    Tasigna Could Boost Novartis’s Revenue Growth in 2018

    In 1Q17, 2Q17, and 3Q17, Tasigna generated revenues of $411 million, $463 million, and $482 million, respectively.

    By Daniel Collins
  • uploads///Chart  Segment Revenues
    Earnings Report

    Behind Novartis’s 4Q17 Earnings: Why Some Expect Revenue Growth

    Analysts expect Novartis’s revenues to rise ~3.9% to $12.8 billion in 4Q17, driven by growth in operating revenues across all three segments.

    By Mike Benson
  • uploads///Chart  Consumer
    Earnings Report

    Johnson & Johnson’s Consumer Segment: 4Q17 Estimates

    Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International.

    By Mike Benson
  • uploads///new organizational structure
    Company & Industry Overviews

    How Teva Pharmaceutical Is Realigning Organizational Structure

    On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Valuation in January 2018

    Mylan (MYL) is a leading pharmaceutical company with over 1,400 generic and specialty pharmaceutical products in its portfolio.

    By Mike Benson
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Valeant on the Street: Analyst Recommendations in December 2017

    Of the 19 analysts tracking Valeant Pharmaceuticals in December 2017, two recommended a “strong buy,” while another two of recommended a “buy.”

    By Daniel Collins
  • uploads///Human insulin
    Company & Industry Overviews

    How Did Novo Nordisk’s NovoMix and Human Insulin Perform in 2017?

    In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///hemophilia
    Company & Industry Overviews

    How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

    In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

    By Daniel Collins
  • uploads///Xarelto
    Company & Industry Overviews

    How Is Johnson & Johnson’s Xarelto Positioned after 3Q17?

    In 3Q17, Johnson & Johnson’s (JNJ) Xarelto generated revenues of $635 million, a ~20% increase on a year-over-year (or YoY) basis and a 1% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Understanding Sanofi’s Revenues by Segment in 3Q17

    Sanofi reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur, or the Human Vaccines segment.

    By Mike Benson
  • uploads///Chart  MRK
    Healthcare

    Behind Merck’s Performance in 3Q17

    MRK stock rose ~0.6% in 3Q17 and has risen ~7.7% YTD (year-to-date) as of October 16.

    By Mike Benson
  • uploads///Chart  Vir
    Company & Industry Overviews

    Bristol-Myers Squibb’s Virology Portfolio

    Bristol-Myers Squibb’s (BMY) virology portfolio includes products for the treatment of chronic virus infections like Hepatitis B virus infections, Hepatitis C virus (or HCV) infections, and HIV infections.

    By Mike Benson
  • uploads///Xultophy
    Company & Industry Overviews

    Xultophy Could Substantially Boost Novo Nordisk’s Revenue Growth

    In the first half of 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of DKK (Danish kroner) 284.0 million.

    By Daniel Collins
  • uploads///Cosentyx
    Company & Industry Overviews

    Why Cosentyx Could Significantly Drive Novartis’s Revenue Growth

    In 1H17, Novartis’s (NVS) Cosentyx generated revenues of around $900 million compared to $436 million in 1H16.

    By Daniel Collins
  • uploads///Sandostatin Afinitor and Exjade
    Company & Industry Overviews

    An Update on Novartis’s Sandostatin, Afinitor, and Exjade

    In 1H17, Novartis’s (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Copaxone
    Company & Industry Overviews

    TEVA Depends on This for Revenue Growth

    In 1H17, Teva Pharmaceutical’s (TEVA) Copaxone reported revenues of ~$2.1 billion, or ~7% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///Chart  Gardasil
    Company & Industry Overviews

    How Merck’s Gardasil and Other Human Vaccines Performed in 2Q17

    Merck’s (MRK) Gardasil franchise includes vaccines for the prevention of certain strains of HPV infections that are sexually transmitted.

    By Mike Benson
  • uploads///Erwinaze
    Company & Industry Overviews

    Where Jazz Pharmaceuticals’ Erwinaze and Prialt Are Positioned after 2Q17

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenues of ~$49 million, which represents a ~1% fall YoY and a ~4% fall QoQ.

    By Daniel Collins
  • uploads///Chart  OPS
    Company & Industry Overviews

    Performance of AstraZeneca’s Other Products in 2Q17

    AstraZeneca’s Other Products segment’s revenues fell 12% at constant exchange rates to ~$1.1 billion during 2Q17.

    By Mike Benson
  • uploads///Chart  GP
    Company & Industry Overviews

    Performance of AstraZeneca’s Growth Platforms in 2Q17

    Emerging markets such as China, Brazil, India, Russia, Mexico, and Turkey reported revenues of ~$1.4 billion during 2Q17, representing 2% growth at constant exchange rates from 2Q16.

    By Mike Benson
  • uploads///Chart  Neuro
    Company & Industry Overviews

    Performance of Eli Lilly’s Neuroscience Products in 2Q17

    Cymbalta’s sales totaled $206.6 million during 2Q17, a 13.0% decline compared to sales of $236.5 million in 2Q16.

    By Mike Benson
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    Changes in GlaxoSmithKline’s Valuation after 2Q17

    As of August 30, 2017, GlaxoSmithKline is trading at a forward PE multiple of 13.3x, which is slightly lower than the industry average of 15.5x.

    By Mike Benson
  • uploads///Chart  Sandoz
    Company & Industry Overviews

    How Novartis’s Sandoz Performed in 2Q17

    Novartis’s Sandoz reported revenues of nearly $2.5 billion in 2Q17, representing ~20% of NVS’s total revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Medical Devices Segment in 2Q17

    Medical devices segment Johnson & Johnson’s (JNJ) medical devices segment reported revenue of $6.7 billion in 2Q17, a growth of 4.9% from the revenue of $6.4 billion reported in 2Q16. This figure included 5.9% growth in operating revenue, and was partially offset by a 1% foreign exchange impact. Cardiovascular care franchise The cardiovascular care franchise […]

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Jazz Pharmaceuticals Is Focused on Label Expansion of Defitelio

    Defitelio could help Jazz Pharmaceuticals become a prominent player not only in the treatment but also in the prevention of post-HSCT complications.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    JAZZ Is Focused on Increasing Market Adoption of Defitelio

    Jazz Pharmaceuticals (JAZZ) expects quarterly variability in Defitelio sales as the drug targets hepatic veno-occlusive disease (or VOD), an ultra-rare condition.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Jazz’s Net Profit Margin Expectations for 2017

    For 2Q17, Jazz Pharmaceuticals (JAZZ) reported revenues close to $394 million, which represented a YoY growth of ~3% and sequential growth ~5%.

    By Margaret Patrick
  • uploads///Chart  SWR
    Company & Industry Overviews

    Sanofi’s Revenue Growth in 2Q17

    Sanofi’s revenue in 2Q17 At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. Structure of the group The above chart shows Sanofi’s segment-wise revenue over the last few quarters. In 2016, Sanofi reorganized itself into five business units: Sanofi […]

    By Mike Benson
  • uploads///Chart  ProductDev
    Company & Industry Overviews

    Pfizer’s Important Product Developments in 2Q17

    Pfizer’s (PFE) innovative health business and essential health business are focusing on growth. To strengthen the innovative health business, the company is focusing on the development of new drugs…

    By Mike Benson
  • uploads///Chart  SWR
    Earnings Report

    GlaxoSmithKline’s 2Q17 Earnings: Business Segments

    GSK reported operational growth of 3% in its revenues to ~7.3 billion pounds for 2Q17.

    By Mike Benson
  • uploads///Chart  Opdivo
    Earnings Report

    Bristol-Myers Squibb’s 2Q17 Earnings: Opdivo

    Bristol-Myers Squibb’s (BMY) blockbuster drug Opdivo reported revenue of $1.2 billion in 2Q17, a 42% rise compared to $840 million in 2Q16.

    By Mike Benson
  • uploads///Chart  NewProducts
    Earnings Report

    Eli Lilly in 2Q17: Performance of New Products

    For 2Q17, Basaglar sales were $86.6 million. Of that, $60.0 million was from sales in the US markets, while $27.0 million was from international sales.

    By Mike Benson
  • uploads///Chart  Ratings
    Earnings Report

    Analysts’ Recommendations for AstraZeneca in 2Q17

    Wall Street analysts expect AstraZeneca’s top line to fall ~9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16. Its earnings per share are expected to be $0.42 in 2Q17.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Inside GlaxoSmithKline’s 2Q17 Earnings Estimates

    For 2Q17, analysts estimate that GSK’s revenues will rise ~11.4% to ~7.3 billion pounds, as compared to ~6.5 billion pounds for 2Q16.

    By Mike Benson
  • uploads///Chart  Segment
    Earnings Report

    Foreign Exchange Impacts Novartis’s Growth in 2Q17

    In its earnings release on July 8, 2017, Novartis (NVS) reported flat revenues at constant currencies for 2Q17.

    By Mike Benson
  • uploads///Chart  Con
    Earnings Report

    Johnson & Johnson: Consumer Products in 2Q17

    The consumer segment Johnson & Johnson’s (JNJ) consumer segment revenue rose 1.7% to $3.5 billion in 2Q17, compared with $3.4 billion in 2Q16. This rise includes operational growth of 2.3%, which was offset by a 0.6% impact of foreign exchange. Baby care franchise The baby care franchise reported revenue of $494 million in 2Q17, a […]

    By Mike Benson
  • uploads///Chart  AR
    Earnings Report

    Analysts’ Latest Recommendations for Johnson & Johnson

    Johnson & Johnson (JNJ) missed Wall Street analysts’ revenue estimates in 1Q17. It reported revenue of $17.8 billion in the quarter.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Novartis’s 2Q17 Earnings: Analyst Estimates

    Novartis is set to release its 2Q17 earnings on July 18, 2017. Analysts estimate EPS (earnings per share) of $1.18 and revenues of $12.3 billion.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Farxiga Could See Robust Demand in International Markets in 2017

    In 1Q17, AstraZeneca’s (AZN) Farxiga reported sales of $42 million in emerging markets, which equals year-over-year growth of ~100% on a reported basis.

    By Margaret Patrick
  • uploads///Chart  LLY
    Company & Industry Overviews

    What We Can Expect from Eli Lilly and Company in 2Q17

    A look at Eli Lilly and Company Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a US pharmaceutical company focused on human pharmaceuticals and animal health. Stock price performance Eli Lilly’s stock price has fallen ~4.4% in 2Q17. However, the stock price had risen 10.9% year-to-date as of July 7, 2017. Analysts’ recommendations Wall […]

    By Mike Benson
  • uploads///Chart  Keytruda
    Company & Industry Overviews

    Keytruda’s Developments in June 2017

    On June 12, 2017, Merck released updated data for Keytruda’s two phase III studies—KEYNOTE-183 and KEYNOTE-185—which evaluate Keytruda in combination with other drugs for the treatment of multiple myeloma.

    By Mike Benson
  • uploads///Chart  Margins
    Company & Industry Overviews

    Pfizer’s Profitability in 1Q17

    Pfizer’s gross margin for 1Q17 was 81.0%, a 0.70% rise compared to 80.3% in 1Q16.

    By Mike Benson
  • uploads///Chart  Val
    Company & Industry Overviews

    Analyzing Bristol-Myers Squibb’s Valuation on June 20

    As of June 20, 2017, Bristol-Myers Squibb was trading at a forward PE multiple of ~18.0x—compared to the industry average of 16.0x.

    By Mike Benson
  • uploads///Chart  SK Biotek
    Company & Industry Overviews

    SK Biotek to Acquire Manufacturing Facility in Swords, Ireland

    In its press release on June 16, 2017, Bristol-Myers Squibb (BMY) announced that it entered into a definitive purchase agreement with SK Biotek.

    By Mike Benson
  • uploads///Chart  PGC
    Company & Industry Overviews

    What Drove Pfizer in 1Q17?

    Growth drivers for Pfizer (PFE) include products contributing to operational growth, such as BMP2, Celebrex, Ibrance, Lyrica, and Xeljanz.

    By Mike Benson
  • uploads///Chart  Sandoz
    Company & Industry Overviews

    Inside Novartis’s Generics Business Now

    Sandoz is also a leader in differentiated generics. Its contribution made up ~21% of Novartis’s total revenues in 1Q17.

    By Mike Benson
  • uploads///Chart  Consumer
    Company & Industry Overviews

    GlaxoSmithKline’s Consumer Healthcare Segment in 1Q17

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment reported an operational growth of 2.0% to ~2.0 billion pounds in 1Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Gardasil and Merck’s Vaccines Business in 1Q17

    Gardasil is Merck’s (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Behind Bristol-Myers Squibb’s 1Q17 Performance

    Bristol-Myers Squibb’s (BMY) top line rose 12% to ~$4.93 billion in 1Q17, driven by an operational growth of 13% in revenues.

    By Mike Benson
  • uploads///Chart  Val
    Earnings Report

    Comparing Pfizer’s Valuation to Peers after 1Q17 Earnings

    Pfizer (PFE) reported a 2% decline in revenues to $12.78 billion in 1Q17, compared to $13.00 billion in 1Q16.

    By Mike Benson
  • uploads///Chart  Consumer
    Earnings Report

    How GlaxoSmithKline’s Consumer Healthcare Segment Fared in 1Q17

    With improvements in the supply chain and the successful launch of new products, GlaxoSmithKline (GSK) is optimistic about its consumer healthcare segment performance in coming years.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.